Global Interstitial Lung Disease Market to Surpass US$ 2453.5 Million by 2028, Says Coherent Market Insights (CMI)
27 déc. 2021 08h30 HE
|
CMI
SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global interstitial lung disease market is estimated to be valued at US$ 1578.9 million in 2021 and is expected...
FibroGen to Present at Upcoming Investor Conferences
02 nov. 2021 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following...
Global Idiopathic Pulmonary Fibrosis Disease Treatment Markets, 2018-2019 & 2020-2024
08 sept. 2021 03h58 HE
|
Research and Markets
Dublin, Sept. 08, 2021 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets" report has been added to ResearchAndMarkets.com's offering.The current report...
Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space
17 août 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space The Idiopathic Pulmonary...
Idiopathic Pulmonary Fibrosis (IPF) Clinical Landscape Report 2021 with 10-Year Disease Incidence and Prevalence Forecasts
13 juil. 2021 05h13 HE
|
Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
11 mai 2021 07h01 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
25 mars 2021 16h05 HE
|
Trevi Therapeutics
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW...
Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
18 févr. 2021 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
25 août 2020 08h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil
05 août 2020 08h37 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...